Information Journal Paper
APA:
Copy. (2018). FDA Approval: Gemtuzumab ozogamicin for the treatment of adults with newly-diagnosed CD33-positive acute myeloid leukemia. CLINICAL CANCER RESEARCH, 24(14), 0-0. SID. https://sid.ir/paper/746566/en
Vancouver:
Copy. FDA Approval: Gemtuzumab ozogamicin for the treatment of adults with newly-diagnosed CD33-positive acute myeloid leukemia. CLINICAL CANCER RESEARCH[Internet]. 2018;24(14):0-0. Available from: https://sid.ir/paper/746566/en
IEEE:
Copy, “FDA Approval: Gemtuzumab ozogamicin for the treatment of adults with newly-diagnosed CD33-positive acute myeloid leukemia,” CLINICAL CANCER RESEARCH, vol. 24, no. 14, pp. 0–0, 2018, [Online]. Available: https://sid.ir/paper/746566/en